Imperial Innovations Group Regulatory News (IVO)

14 Jan 2008 10:30

Imperial Innovations Group plc14 January 2008 Imperial Innovations Group plc ("Imperial Innovations") Commercialisation deals signed Imperial Innovations Group plc (AIM: IVO), today announces that it has signedcommercialisation contracts with a number of healthcare organisations. • Two licences relating to research tools have been concluded with Novartis Institutes for BioMedical Research, Inc. and Alcon, Inc. a global company specialised in eye care products. • Patents on Eotaxin and corresponding antibodies for research applications have been licensed to Invitrogen Corporation, a leading international supplier of reagents for the life sciences and biomedicine. Eotaxin is a protein associated with the migration of white blood cells to inflammatory tissues in disease states, and is currently the subject of intensive research. • An option agreement has been signed with Emiliem, Inc. a biopharmaceutical company developing molecular targeted cancer therapies, for a family of patents relating to an inhibitor of Protein Kinase B (PKB or Akt), which is a validated cancer target. Susan Searle, CEO Imperial Innovations said, "The Biosciences team at ImperialInnovations have been working hard to source and market technologies, findsuitable commercialisation partners and conclude these deals. These four dealsadded to our portfolio demonstrate the continuing breadth of opportunitiescoming through our technology pipeline." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsEleanor Williamson / Harriet Totty +44 (0)20 7153 1539 JP Morgan Cazenove (NOMAD to Imperial Innovations)Steve Baldwin +44(0)20 7588 2828 Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £25 million at an offer price of 365p and £1 million by meansof a public offer. In November 2007, the company raised a further £30 million bymeans of a placing of new ordinary shares with investors. The company's integrated approach encompasses the identification of ideas,protection of intellectual property, development and licensing of technology andformation, incubation and investment in technology businesses. A wide range oftechnologies are commercialised within the areas of healthcare, energy,environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in74 technology businesses and is managing 133 commercial agreements as of 31 July2007. Imperial Innovations also commercialises technologies originating fromoutside Imperial College through incubation contracts with the Carbon Trust andWRAP and has commercialisation contracts with a number of multinationalcorporations including BAE Systems. www.imperialinnovations.co.uk This information is provided by RNS The company news service from the London Stock Exchange